Expand STOK Menu
STOK MENU

STOK Latest Press Releases

-- June 30, 2026 --

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome Business Wire 8:00 AM

-- June 16, 2026 --

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire 4:01 PM

-- May 28, 2026 --

Stoke Therapeutics to Present at Upcoming Investor Conferences in June Business Wire 4:01 PM

-- May 18, 2026 --

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire 4:01 PM

-- May 7, 2026 --

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates Business Wire 4:01 PM

-- April 30, 2026 --

Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates Business Wire 4:01 PM

-- April 16, 2026 --

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire 4:01 PM

-- April 8, 2026 --

Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference Business Wire 4:01 PM
The Credibility Filter Wall Street Uses to Sort Biotech Winners Globe Newswire 9:15 AM

-- April 7, 2026 --

Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors Business Wire 4:01 PM

-- March 17, 2026 --

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire 5:12 PM

-- March 4, 2026 --

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome Business Wire 5:06 PM
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome Globe Newswire 5:05 PM

-- February 24, 2026 --

Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference Business Wire 4:01 PM

-- February 18, 2026 --

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire 4:01 PM

-- February 11, 2026 --

Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA) Business Wire 7:30 AM
Market Data Delayed 15 Minutes